摘要
目的 :用不同方法比较示踪剂量与治疗剂量13 1I早期摄取率 ,为临床治疗甲状腺功能亢进症提供依据 .方法 :弥漫性甲状腺肿伴甲亢患者 10 8例 ,分别用甲状腺功能仪及SPECT的感兴趣区法 (ROI)测定甲状腺摄13 1I率 ,比较得出两种剂量摄13 1I率的关系 .结果 :用甲状腺功能仪方法测出的甲状腺摄13 1I率示踪剂量均低于治疗剂量 (P <0 .0 1) ,两种方法之间存在统计学差异 (F =5 3.6 4 ,P <0 .0 1) ;而SPECT的感兴趣区 (ROI)法测得的 2 4h甲状腺摄13 1I率治疗剂量与示踪剂量无显著性差异 (t=1.14 ,P >0 .0 5 ) ,SPECT的治疗剂量ROI法和甲状腺功能仪的示踪剂量法之间无统计学意义(F =0 .17,P >0 .0 5 ) .结论 :甲状腺功能仪测定的示踪剂量2 4h摄13 1I率完全反映治疗剂量甲状腺摄13 1I率 ;用SPECT的ROI法可测定治疗剂量的甲状腺摄13 1I率 .
AIM: To compare early radioiodine thyroid uptake ratio between tracer and therapeutic dose with different methods. METHODS: Thyroid function instrument and the region of interest (ROI) method on SPECT were performed in 108 patients with hyperthyroidism to measure thyroid uptake ratio (TUR) of tracer and therapeutic 131 I dose. RESULTS: TUR of tracer 131 I dose was lower than that of therapeutic dose using thyroid function instrument at 4, 6, 24 h ( F=53.64, P <0.01). However, no significant difference was determined by using ROI methods at 24 h ( t=1.14, P >0.05). Furthermore, there was also no significant difference between TUR of tracer dose at 24 h with thyroid function instrument and that of therapeutic dose at 24 h using ROI method ( P >0.05). There was no significant difference in two methods of tracer dose ( F=0.17, P >0.05). CONCLUSION: Radioiodine thyroid uptake ratio of tracer dose can reflect completely that of therapeutic dose. The method of ROI can be used to measure TUR of therapeutic dose.
出处
《第四军医大学学报》
CAS
北大核心
2003年第12期1124-1126,共3页
Journal of the Fourth Military Medical University
